Document Detail

Repurposing the Pap smear: one step closer to gynecologic cancer screening.
MedLine Citation:
PMID:  23303602     Owner:  NLM     Status:  MEDLINE    
Prevention and early detection remain essential to decreasing cancer mortality. Screening DNA in Pap smears has the potential to increase the rate of early detection of endometrial and ovarian cancers. In this issue of Science Translational Medicine, Kinde and colleagues use advanced sequencing technology to evaluate DNA to screen for gynecologic malignancies.
Shannon N Westin; Gordon B Mills; Andrea P Myers
Publication Detail:
Type:  Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Science translational medicine     Volume:  5     ISSN:  1946-6242     ISO Abbreviation:  Sci Transl Med     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-10     Completed Date:  2013-06-11     Revised Date:  2014-09-19    
Medline Journal Info:
Nlm Unique ID:  101505086     Medline TA:  Sci Transl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  167ps1     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
DNA, Neoplasm / analysis*
Endometrial Neoplasms / diagnosis*
Ovarian Neoplasms / diagnosis*
Papanicolaou Test*
Vaginal Smears*
Grant Support
2P50 CA098258-06/CA/NCI NIH HHS; K12 CA088084/CA/NCI NIH HHS; P50 CA083639/CA/NCI NIH HHS; P50 CA098258/CA/NCI NIH HHS
Reg. No./Substance:
0/DNA, Neoplasm
Comment On:
Sci Transl Med. 2013 Jan 9;5(167):167ra4   [PMID:  23303603 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhanced Oxygen Reduction Reactions in Fuel Cells on H-Decorated and B-Substituted Graphene.
Next Document:  Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.